PDF(Pubmed)
Abstract：
Bladder cancer stands as one of the prevalent malignancies in urological clinics, highlighting the pressing need to uncover prognostic or therapeutic avenues. ITM2A, a transmembrane protein, has been identified as a suppressor in tumor progression recently. Our study underscored a significant correlation between low ITM2A expression in bladder cancer tissues and high tumor grade, AJCC stage, and poor overall survival time. Additionally, our findings demonstrated that reinstating ITM2A expression impeded cell proliferation, migration, and invasion, while conversely, its suppression enhanced these malignant behaviors. Furthermore, we elucidated that ITM2A could suppress malignant phenotypes of bladder cancer cells via inhibiting activation of the STAT3 induced by IL-6. In conclusion, our research unveiled the mechanistic role of ITM2A in inhibiting tumor progression, shedding light on its potential as a prognostic predictor and therapeutic target in bladder cancer management.
摘要：
膀胱癌是泌尿外科诊所中常见的恶性肿瘤之一，强调迫切需要揭示预后或治疗途径。ITM2A,跨膜蛋白，最近已被确定为肿瘤进展的抑制剂。我们的研究强调了膀胱癌组织中的低ITM2A表达与高肿瘤分级之间的显着相关性。AJCC阶段，总体生存时间差。此外,我们的研究结果表明，恢复ITM2A表达会阻碍细胞增殖，迁移,和入侵,而反过来,它的抑制增强了这些恶性行为。此外，我们阐明了ITM2A可以通过抑制IL-6诱导的STAT3的激活来抑制膀胱癌细胞的恶性表型。总之,我们的研究揭示了ITM2A在抑制肿瘤进展中的机制作用，阐明其在膀胱癌治疗中作为预后预测因子和治疗靶标的潜力。
